Emerging Agents in GVHD: Axatilimab

The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.

Related Keywords

Dana Farber Cancer Institute ,Massachusetts ,United States ,Corey Cutler ,Hannah Choe ,Mitchell Horwitz ,Bin Chen ,Ohio State University ,Marrow Transplant Program At Duke University ,Professor Of Medicine At Harvard Medical School ,Cell Therapy Program At Massachusetts ,Cell Therapy Program ,Massachusetts General Hospital ,Harvard Medical School ,Stem Cell Transplant Program ,Adult Blood ,Marrow Transplant Program ,Duke University ,Assistant Professor ,Ohio State ,Chronic Graft Versus Host Disease ,Cgvhd ,Csf 1r Inhibitor ,Iv Infusion ,Agave 201 ,Ruxolitinib ,Ibrutinib ,Belumosudil ,Ast Alt Levels ,Combination Therapy ,Dash Conference ,Monoclonal Antibody ,Kupffer Cells ,